Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
  • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• This invention relates to novel amino acid derivatives and non-toxic salts thereof, to methods of preparing these compounds, to pharmaceutical compositions containing them as active ingredients, and to a method of using them as antihypertensives.
• the present invention relates to a novel class of compounds represented by the formula ##STR2## wherein R 1 represents hydrogen, alkyl of 1 to 6 carbon atoms or phenylalkyl of 7 to 12 carbon atoms;
• R 2 represents hydrogen, alkyl of 1 to 4 carbon atoms or phenylalkyl of 7 to 12 carbon atoms;
• R 3 represents hydrogen or alkyl of 1 to 6 carbon atoms
• n and m each represent 0, 1 or 2, the sum of n and m being 1 or 2;
• X, Y and Z each represent oxygen, sulfur, --NR 4 --, ⁇ CR 5 --, --CHR 5 --, ##STR3## provided that only one of the radicals X, Y and Z can represent O, S, ##STR4## and one or two of the radicals X, Y and Z can represent --NR 4 --;
• R 4 represents hydrogen or alkyl of 1 to 4 carbon atoms;
• the five- or six-membered heterocycles condensed on the pyrrolidino- or piperidino-carboxylic acid can be saturated or unsaturated.
• Preferred heterocycles are: furan, pyrrole, thiophene, benzofuran, indole, benzothiophene, oxazole, imidazole, thiazole, isoxazole, pyrazole, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, pyridine, pyridazine, quinoline, isoquinoline or piperidine.
• the new compounds generally have several asymmetric centers and may therefore be present as diastereoisomers or in the form of racemates or racemic mixtures.
• the invention embraces both the racemic mixtures and the individual diasteroisomers. Those enantiomers in which the symmetric carbon atoms are present in the L-configuration are preferred.
• the compounds of formula I can be present as internal salts or, if there are free carboxyl groups, as alkali metal or alkaline earth metal salts, for example as sodium, potassium, magnesium or calcium salts, or as non-toxic salts with amines such as trimethylamine or dicyclohexylamine. Furthermore, a free amino group present can be reacted with a mineral acid, such as hydrochloric acid or hydrobromic acid, or an organic acid, for example acetic acid, to form a non-toxic acid addition salt.
• a mineral acid such as hydrochloric acid or hydrobromic acid
• organic acid for example acetic acid
• the compounds of the formula I can be prepared by the following methods:
• U represents an amino group or, conversely, T represents an amino group and U a nucleofuge group
• R 6 represents hydrogen, alkyl of 1 to 4 carbon atoms, a benzyl group or a trimethylsilyl group, and
• R 1 , R 2 , R 3 , n, m, X, Y and Z have the meanings given above.
• Halides can serve as nucleofuges, so that, for example, the process can start from 2-halo-carboxylic acid derivatives and 2-amino acid derivatives.
• the reaction is preferably carried out in polar solvents such as water, alcohols, dimethylformamide, acetonitrile, dimethylsulfoxide or mixtures thereof, optionally in the presence of an alkali metal or alkaline earth metal carbonate, tertiary amines, quaternary ammonium hydroxides or tetraalkylguanidines.
• polar solvents such as water, alcohols, dimethylformamide, acetonitrile, dimethylsulfoxide or mixtures thereof, optionally in the presence of an alkali metal or alkaline earth metal carbonate, tertiary amines, quaternary ammonium hydroxides or tetraalkylguanidines.
• Condensation can be carried out according to methods described in Houben-Weyl, Methods of Organic Chemistry, Volume 15.
• a preferred condensation agent for the reaction is N,N'-dicyclohexyl-carbodiimide, and a preferred carboxyl protective group for the amino acid VI is the tert.butyl-, benzyl- or trimethylsilyl group. After condensation has been carried out, this can be split off according to the conventional methods such as those described in the examples below.
• the benzyloxycarbonyl or the fluorenylmethoxycarbonyl group are preferably used as amino protective groups, and N,N'-dicyclohexylcarbodiimide is preferably used as the condensation agent.
• the starting compounds of the formula VI can be obtained, depending on the meaning of the radicals X, Y and Z, for example by reacting
• the starting compounds can be present in the form of racemic mixtures, diastereoisomers or enantiomers. If there are racemic mixtures, the sterically unitary forms can be enriched or obtained pure from the reaction products according to conventional methods such as fractional crystallization or chromatographic processes.
• the dimethylformamide was distilled off in vacuo, the residue was dissolved in ethyl acetate, washed with water, KHSO 4 solution and water, dried over MgSO 4 and evaporated. The residue was chromatographed on silica gel [eluant: dichloromethane, methanol, ethyl acetate (20:1:2)]. 13.9 g (60% of theory) of the title compound were isolated as a colorless oil.
• 650 mg of dicyclohexylcarbodiimide were added to a solution of 716 mg of methyl 6,7-dihydro-thieno[2,3-c]-pyridine-5-carboxylate hydrochloride, 1 g of N-(L-ethoxycarbonyl-3-phenylpropyl)-L-alanine, 0.5 g of 1-hydroxybenzotriazole and 620 mg of triethylamine in 50 ml tetrahydrofuran/dimethylformamide (1:1), cooled to 0° C. The mixture was stirred for one hour at 0° C.
• Example 8 3.1 g of the title compound (70% of theory) were obtained from 4.6 g of methyl N-[N-(L-1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-L-4-carboxylate (described as intermediate in Example 9) and 10 ml of 1N NaOH as a colorless powder, m.p. 133°-135° C.
• Example 8 Using the procedure of Example 8, 2.4 g of the title compound (55% of theory) were obtained from 4.6 g of methyl N-[N-(L-1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-L-7-carboxylate and 10 ml of 1N NaOH as a colorless powder, m.p. 75° C. (dec.).
• the new end products of the formula I exhibit strong, long-lasting hypotensive activity. This is based on an inhibition of the angiotensin I-converting enzyme and consequent blocking of the formation of the vasoconstrictor angiotensin II from angiotensin I. Furthermore, the new compounds have an inhibiting effect on the enzyme kininase II which is responsible for bradykinin decomposition and which is considered identical to the converting enzyme mentioned above. Since bradykinin has a vasodilatory effect, the hypotensive effect is reinforced by this additional effect. The lowering of blood pressure in normal rats, which is produced by means of bradykinin, is reinforced by the new compounds.
• Administration can be intravenous, subcutaneous or oral.
• the dosage in oral administration is around 20-200 mg per individual dose.
• intravenous administration, or in simultaneous administration with diuretics it is appropriate to reduce the dose.
• the new compounds are mixed with conventional pharmaceutical fillers or carriers, extenders, disintegrating agents, binders, entrainers, thickeners or diluents.
• the pharmaceutical preparation forms to be considered are, for example, tablets, capsules, suppositories, solutions, juices, emulsions or dispersable powders, and if desired further known active substances, for example, saluretics, diuretics and/or anti-hypotonics, can be added.
• Appropriate tablets can be obtained, for example, by mixing the active substance or substances with known excipients, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrating agents, such as corn starch or algenic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and/or agents for achieving a sustained-release effect, such as carboxypolymethylene, carboxymethylcellulose, cellulose acetate phthalate or polyvinyl acetate.
• the tablets can also consist of several layers.
• coated tablets can be prepared by covering cores produced analogous to the tablets with agents used conventionally in coated tablet coverings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar.
• the core can also consist of several layers.
• the coated tablet envelope can consist of several layers to achieve a sustained-release effect, and the excipients mentioned above as regards the tablets can be used.
• Juices of the active substances or active substance combinations according to the invention can additionally also contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, and a flavor improving agent, for example, aromatics such as vanillin or orange extract. They can also contain suspension excipients or thickeners, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective substances, such as p-hydroxybenzoates.
• a sweetener such as saccharin, cyclamate, glycerol or sugar
• a flavor improving agent for example, aromatics such as vanillin or orange extract.
• They can also contain suspension excipients or thickeners, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective substances, such as p-hydroxybenzoates.
• Injection solutions are prepared in a conventional way, for example by adding preserving agents, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediamine tetraacetic acid, and by adding suitable solubilizers, and can be filled into injection bottles or ampules.
• preserving agents such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediamine tetraacetic acid
• Capsules containing one or more active substances or active-substance combinations can be prepared, for example, by mixing the active substances with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatin capsules.
• inert carriers such as lactose or sorbitol
• compositions comprising a compound of the present invention as an active ingredient and represent the best modes contemplated of using the invention.
• the parts are parts by weight unless otherwise specified.
• the tablet core composition is compounded from the following ingredients:
• the mixture of the active ingredient with lactose and corn starch is granulated with an aqueous 10% gelatin solution through a screen with a mesh width of 1 mm, dried at 40° C. and again passed through the screen.
• the granulate obtained in this way is mixed with magnesium stearate, and the mixture is processed into 200 mg-tablet cores.
• the cores obtained in this way are covered in conventional manner with a thin shell consisting of a mixture of sugar, titanium dioxide, talc and gum arabic.
• the finished coated tablets are polished with beeswax.
• the tablet composition is compounded from the following ingredients:
• the active ingredient and magnesium stearate are granulated with an aqueous solution of the soluble starch, the granulate is dried and mixed intimately with lactose and corn starch. The mixture is then compressed into tablets weighing 230 mg, each of which contains 100 mg of active ingredient.
• the solution is compounded from the following ingredients:
• the active ingredient and excipients are dissolved in a sufficient quantity of distilled water and the solution is brought to the desired concentration by means of the necessary quantity of water.
• the solution is filtered and filled into 2 ml-ampules under aseptic conditions. Each ampule contains 50 mg of active ingredient.
• the capsule filler composition is compounded from the following ingredients:
• the active ingredient, lactose and corn starch are first mixed in a mixer and then in a comminuting machine.
• the mixture is introduced into the mixer again, mixed thoroughly with the talc, and 400 mg-portions are filled into hard gelatin capsules by machine.
• Each capsule contains 100 mg of active ingredient.
• the suppository composition is compounded from the following ingredients:
• the cocoa butter and carnabua wax are melted, mixed thoroughly and cooled to 45° C.
• the finely pulverized active ingredient is stirred into this mixture.
• 1.8 g-portions of the mixture are poured into slightly precooled suppository molds of suitable size and allowed to cool.
• Each suppository contains 100 mg of active ingredient.
• any one of the other compounds embraced by formula I or a non-toxic, pharmacologically acceptable salt thereof may be substituted for the particular active ingredient in Examples 12 through 16.
• the amount of active ingredient in these illustrative examples may be varied to achieve the dosage unit range set forth above, and the amounts and nature of the inert pharmaceutical carrier ingredients may be varied to meet particular requirements.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=6188976

Family Applications (4)

Family Applications After (3)

Country Status (12)

Cited By (5)

Families Citing this family (11)

Family Cites Families (13)

• 1983
  • 1983-01-22 DE DE19833302125 patent/DE3302125A1/de not_active Withdrawn
• 1984
  • 1984-01-13 EP EP84100314A patent/EP0116842A3/de not_active Withdrawn
  • 1984-01-19 US US06/572,179 patent/US4555511A/en not_active Expired - Fee Related
  • 1984-01-19 FI FI840206A patent/FI81106C/fi not_active IP Right Cessation
  • 1984-01-20 ZA ZA84439A patent/ZA84439B/xx unknown
  • 1984-01-20 ES ES529035A patent/ES8505518A1/es not_active Expired
  • 1984-01-20 IL IL70728A patent/IL70728A0/xx unknown
  • 1984-01-20 DK DK26784A patent/DK26784A/da not_active Application Discontinuation
  • 1984-01-20 NO NO840212A patent/NO162619C/no unknown
  • 1984-01-20 AU AU23645/84A patent/AU567124B2/en not_active Ceased
  • 1984-01-23 JP JP59009931A patent/JPS59139382A/ja active Pending
  • 1984-01-23 CA CA000445865A patent/CA1243032A/en not_active Expired
• 1985
  • 1985-06-27 US US06/749,473 patent/US4683238A/en not_active Expired - Fee Related
• 1987
  • 1987-05-06 US US07/047,417 patent/US4766129A/en not_active Expired - Fee Related
• 1988
  • 1988-05-26 US US07/199,121 patent/US4826855A/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events